{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:38:47Z","timestamp":1792795127743,"version":"4.5.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01798-z","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:52:54Z","timestamp":1779677574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regimen-Related Oral Mucosal Injury: Pathobiology, Clinical Consequences and Rationale for Intervention Across Cancer Treatment Modalities"],"prefix":"10.1007","volume":"28","author":[{"given":"Stephen","family":"Sonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wardill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"1798_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc1318","volume":"4","author":"ST Sonis","year":"2004","unstructured":"Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277\u201384. https:\/\/doi.org\/10.1038\/nrc1318.","journal-title":"Nat Rev Cancer"},{"key":"1798_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3322\/caac.21704","volume":"72","author":"S Elad","year":"2022","unstructured":"Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022;72:57\u201377. https:\/\/doi.org\/10.3322\/caac.21704.","journal-title":"CA Cancer J Clin"},{"key":"1798_CR3","first-page":"182","volume":"28","author":"CW Prowd","year":"1933","unstructured":"Prowd CW. The Radiation Treatment of Intra-Oral Cancer. Can Med Assoc J. 1933;28:182\u20134.","journal-title":"Can Med Assoc J"},{"key":"1798_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM194806032382301","volume":"238","author":"S Farber","year":"1948","unstructured":"Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787\u201393. https:\/\/doi.org\/10.1056\/NEJM194806032382301.","journal-title":"N Engl J Med"},{"key":"1798_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJM199003083221022","volume":"322","author":"AH Balter","year":"1990","unstructured":"Balter AH, Stomatitis. N Engl J Med. 1990;322:704. https:\/\/doi.org\/10.1056\/NEJM199003083221022.","journal-title":"N Engl J Med"},{"key":"1798_CR6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1200\/JCO.2007.13.6028","volume":"26","author":"N Blijlevens","year":"2008","unstructured":"Blijlevens N, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy\u2013European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26:1519\u201325. https:\/\/doi.org\/10.1200\/JCO.2007.13.6028.","journal-title":"J Clin Oncol"},{"key":"1798_CR7","doi-asserted-by":"publisher","first-page":"9141","DOI":"10.1007\/s00520-022-07328-4","volume":"30","author":"M Nakagaki","year":"2022","unstructured":"Nakagaki M, Kennedy GA, Gavin NC, Clavarino A, Whitfield K. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation. Support Care Cancer. 2022;30:9141\u20139. https:\/\/doi.org\/10.1007\/s00520-022-07328-4.","journal-title":"Support Care Cancer"},{"key":"1798_CR8","doi-asserted-by":"publisher","first-page":"102675","DOI":"10.1016\/j.eclinm.2024.102675","volume":"73","author":"R Abdalla-Aslan","year":"2024","unstructured":"Abdalla-Aslan R, et al. Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. EClinicalMedicine. 2024;73:102675. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102675.","journal-title":"EClinicalMedicine"},{"key":"1798_CR9","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.ijgc.2025.101997","volume":"35","author":"MDS Lightfoot","year":"2025","unstructured":"Lightfoot MDS, et al. Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment. Int J Gynecol Cancer. 2025;35:101997. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101997.","journal-title":"Int J Gynecol Cancer"},{"key":"1798_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/odi.12795","volume":"24","author":"L Lo Muzio","year":"2018","unstructured":"Lo Muzio L, Arena C, Troiano G, Villa A. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. Oral Dis. 2018;24:144\u201371. https:\/\/doi.org\/10.1111\/odi.12795.","journal-title":"Oral Dis"},{"key":"1798_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11523-024-01073-w","volume":"19","author":"S Zhou","year":"2024","unstructured":"Zhou S, Kishi N, Alerasool P, Rohs NC. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis. Target Oncol. 2024;19:547\u201364. https:\/\/doi.org\/10.1007\/s11523-024-01073-w.","journal-title":"Target Oncol"},{"key":"1798_CR12","doi-asserted-by":"publisher","unstructured":"Arena C, Troiano G, De Lillo A, Testa NF, Lo Muzio L. Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients. Biomed Res Int. 2018. https:\/\/doi.org\/10.1155\/2018\/5035217.","DOI":"10.1155\/2018\/5035217"},{"key":"1798_CR13","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/cncr.33436","volume":"127","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wen N, Sonis ST, Villa A. Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women\u2019s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer. 2021;127:1796\u2013804. https:\/\/doi.org\/10.1002\/cncr.33436.","journal-title":"Cancer"},{"key":"1798_CR14","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1002\/hed.27646","volume":"46","author":"K Al-Eryani","year":"2024","unstructured":"Al-Eryani K, Epstein JB, Monreal AV, Villa A. Orofacial complications from immune checkpoint inhibitors: A retrospective analysis from two academic medical centers. Head Neck. 2024;46:1865\u201372. https:\/\/doi.org\/10.1002\/hed.27646.","journal-title":"Head Neck"},{"key":"1798_CR15","doi-asserted-by":"publisher","unstructured":"Moore ZR et al. Risk of Unplanned Hospital Encounters in Patients Treated With Radiotherapy for Head and Neck Squamous Cell Carcinoma. J Pain Symptom Manage, 2019, 57, 738\u2013745 e733. https:\/\/doi.org\/10.1016\/j.jpainsymman.2018.12.337","DOI":"10.1016\/j.jpainsymman.2018.12.337"},{"key":"1798_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00520-023-07770-y","volume":"31","author":"E Fahy","year":"2023","unstructured":"Fahy E, Brooker RC, Fleming JC, Patterson JM. A review of unplanned admissions in head and neck cancer patients undergoing oncological treatment. Support Care Cancer. 2023;31:328. https:\/\/doi.org\/10.1007\/s00520-023-07770-y.","journal-title":"Support Care Cancer"},{"key":"1798_CR17","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/cancers7030862","volume":"7","author":"M Bonomi","year":"2015","unstructured":"Bonomi M, Batt K. Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients. Cancers (Basel). 2015;7:1743\u201357. https:\/\/doi.org\/10.3390\/cancers7030862.","journal-title":"Cancers (Basel)"},{"key":"1798_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cncr.21622","volume":"106","author":"M Vera-Llonch","year":"2006","unstructured":"Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106:329\u201336. https:\/\/doi.org\/10.1002\/cncr.21622.","journal-title":"Cancer"},{"key":"1798_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1634\/theoncologist.2008-0024","volume":"13","author":"G Russo","year":"2008","unstructured":"Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008;13:886\u201398. https:\/\/doi.org\/10.1634\/theoncologist.2008-0024.","journal-title":"Oncologist"},{"key":"1798_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.rpor.2015.05.010","volume":"20","author":"JA Gonzalez Ferreira","year":"2015","unstructured":"Gonzalez Ferreira JA, Olasolo J, Azinovic J, I., Jeremic B. Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Rep Pract Oncol Radiother. 2015;20:328\u201339. https:\/\/doi.org\/10.1016\/j.rpor.2015.05.010.","journal-title":"Rep Pract Oncol Radiother"},{"key":"1798_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamaoto.2025.4203","volume":"152","author":"LA Gharzai","year":"2026","unstructured":"Gharzai LA, et al. Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Otolaryngol Head Neck Surg. 2026;152:144\u201353. https:\/\/doi.org\/10.1001\/jamaoto.2025.4203.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"1798_CR22","first-page":"231","volume":"5","author":"M Vera-Llonch","year":"2007","unstructured":"Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol. 2007;5:231\u20135.","journal-title":"J Support Oncol"},{"key":"1798_CR23","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1200\/JCO.2001.19.8.2201","volume":"19","author":"ST Sonis","year":"2001","unstructured":"Sonis ST, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201\u20135. https:\/\/doi.org\/10.1200\/JCO.2001.19.8.2201.","journal-title":"J Clin Oncol"},{"key":"1798_CR24","doi-asserted-by":"publisher","unstructured":"Blijlevens NMA, de Mooij CEM. Mucositis and Infection in Hematology Patients. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24119592.","DOI":"10.3390\/ijms24119592"},{"key":"1798_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00520-023-07654-1","volume":"31","author":"PS Satheeshkumar","year":"2023","unstructured":"Satheeshkumar PS, Blijlevens N, Sonis ST. Application of big data analyses to compare the impact of oral and gastrointestinal mucositis on risks and outcomes of febrile neutropenia and septicemia among patients hospitalized for the treatment of leukemia or multiple myeloma. Support Care Cancer. 2023;31:199. https:\/\/doi.org\/10.1007\/s00520-023-07654-1.","journal-title":"Support Care Cancer"},{"key":"1798_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40273-013-0081-2","volume":"31","author":"A Carlotto","year":"2013","unstructured":"Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. PharmacoEconomics. 2013;31:753\u201366. https:\/\/doi.org\/10.1007\/s40273-013-0081-2.","journal-title":"PharmacoEconomics"},{"key":"1798_CR27","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1007\/s00520-016-3337-5","volume":"24","author":"S Elad","year":"2016","unstructured":"Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016;24:4825\u201330. https:\/\/doi.org\/10.1007\/s00520-016-3337-5.","journal-title":"Support Care Cancer"},{"key":"1798_CR28","doi-asserted-by":"publisher","unstructured":"Mohammed AI, et al. Assessment of Oxidative Stress-Induced Oral Epithelial Toxicity. Biomolecules. 2023;13. https:\/\/doi.org\/10.3390\/biom13081239.","DOI":"10.3390\/biom13081239"},{"key":"1798_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1601-0825.2010.01681.x","volume":"16","author":"ST Sonis","year":"2010","unstructured":"Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010;16:597\u2013600. https:\/\/doi.org\/10.1111\/j.1601-0825.2010.01681.x.","journal-title":"Oral Dis"},{"key":"1798_CR30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00520-024-08752-4","volume":"32","author":"AM Stringer","year":"2024","unstructured":"Stringer AM, et al. Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC\/ISOO framework. Support Care Cancer. 2024;32:558. https:\/\/doi.org\/10.1007\/s00520-024-08752-4.","journal-title":"Support Care Cancer"},{"key":"1798_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s005200050004","volume":"8","author":"JE Raber-Durlacher","year":"2000","unstructured":"Raber-Durlacher JE, et al. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer. 2000;8:366\u201371. https:\/\/doi.org\/10.1007\/s005200050004.","journal-title":"Support Care Cancer"},{"key":"1798_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-006-0055-4","volume":"14","author":"JA Jones","year":"2006","unstructured":"Jones JA, et al. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14:505\u201315. https:\/\/doi.org\/10.1007\/s00520-006-0055-4.","journal-title":"Support Care Cancer"},{"key":"1798_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00520-024-08733-7","volume":"32","author":"Y Saito","year":"2024","unstructured":"Saito Y, Takekuma Y, Takahashi M, Oshino T, Sugawara M. Association of oral mucositis induced by anthracycline-cyclophosphamide and subsequent docetaxel treatment for perioperative breast cancer. Support Care Cancer. 2024;32:513. https:\/\/doi.org\/10.1007\/s00520-024-08733-7.","journal-title":"Support Care Cancer"},{"key":"1798_CR34","doi-asserted-by":"publisher","unstructured":"Lalla RV, et al. Oral Mucositis Due to High-Dose Chemotherapy and\/or Head and Neck Radiation Therapy. J Natl Cancer Inst Monogr. 2019. https:\/\/doi.org\/10.1093\/jncimonographs\/lgz011.","DOI":"10.1093\/jncimonographs\/lgz011"},{"key":"1798_CR35","unstructured":"Head and Neck Cancer Disease Site Group. Accelerated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. (2000)."},{"key":"1798_CR36","unstructured":"In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. (Centre for Reviews and Dissemination (UK), 1995). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK285222\/"},{"key":"1798_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","volume":"13","author":"J Bourhis","year":"2012","unstructured":"Bourhis J, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99\u2009\u2013\u200902): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13:145\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(11)70346-1.","journal-title":"Lancet Oncol"},{"key":"1798_CR38","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"KK Ang","year":"2014","unstructured":"Ang KK, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32:2940\u201350. https:\/\/doi.org\/10.1200\/JCO.2013.53.5633.","journal-title":"J Clin Oncol"},{"key":"1798_CR39","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1007\/s00520-020-05579-7","volume":"28","author":"HR Wardill","year":"2020","unstructured":"Wardill HR, et al. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer. 2020;28:5059\u201373. https:\/\/doi.org\/10.1007\/s00520-020-05579-7.","journal-title":"Support Care Cancer"},{"key":"1798_CR40","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12672-025-02458-7","volume":"16","author":"Y Liang","year":"2025","unstructured":"Liang Y, Wang X, Shi X, Fei X. Risk factors and prediction models for severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing chemoradiotherapy. Discov Oncol. 2025;16:903. https:\/\/doi.org\/10.1007\/s12672-025-02458-7.","journal-title":"Discov Oncol"},{"key":"1798_CR41","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","volume":"40","author":"JM Unger","year":"2022","unstructured":"Unger JM, et al. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. J Clin Oncol. 2022;40:1474\u201386. https:\/\/doi.org\/10.1200\/JCO.21.02377.","journal-title":"J Clin Oncol"},{"key":"1798_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/00220345251392081","volume":"33","author":"CL Kirkwood","year":"2026","unstructured":"Kirkwood CL, Zhang L, Kirkwood KL. Exploring the Influence of Sex on the Development of Radiation-Induced Oral Mucositis. Adv Dent Res. 2026;33:9\u201312. https:\/\/doi.org\/10.1177\/00220345251392081.","journal-title":"Adv Dent Res"},{"key":"1798_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.48095\/ccko2024189","volume":"37","author":"HA Hirna","year":"2024","unstructured":"Hirna HA, Maltsev DV, Kostyshyn ID, Holotiuk VV. Results of the study of factors predicting the risk of the development of grade III radiation-induced mucositis during radiation or chemoradiation therapy in patients with oral cavity and oropharynx cancer. Klin Onkol. 2024;37:189\u2013201. https:\/\/doi.org\/10.48095\/ccko2024189.","journal-title":"Klin Onkol"},{"key":"1798_CR44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/SPC.0000000000000339","volume":"12","author":"PC Bachour","year":"2018","unstructured":"Bachour PC, Sonis ST. Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges. Curr Opin Support Palliat Care. 2018;12:198\u2013210. https:\/\/doi.org\/10.1097\/SPC.0000000000000339.","journal-title":"Curr Opin Support Palliat Care"},{"key":"1798_CR45","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cpt.3567","volume":"117","author":"TT Ho","year":"2025","unstructured":"Ho TT, et al. A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice. Clin Pharmacol Ther. 2025;117:1194\u2013208. https:\/\/doi.org\/10.1002\/cpt.3567.","journal-title":"Clin Pharmacol Ther"},{"key":"1798_CR46","doi-asserted-by":"publisher","first-page":"218234","DOI":"10.1016\/j.canlet.2025.218234","volume":"640","author":"CB Cross","year":"2026","unstructured":"Cross CB, et al. Pre-treatment gut microbiome and salivary metabolome signatures associate with chemotherapy-induced cognitive decline in women with breast cancer: A prospective pilot study. Cancer Lett. 2026;640:218234. https:\/\/doi.org\/10.1016\/j.canlet.2025.218234.","journal-title":"Cancer Lett"},{"key":"1798_CR47","doi-asserted-by":"publisher","first-page":"1138992","DOI":"10.3389\/fonc.2023.1138992","volume":"13","author":"L Huang","year":"2023","unstructured":"Huang L, Ye X, Wu F, Wang X, Qiu M. Study of prevalence and risk factors of chemotherapy-induced mucositis in gastrointestinal cancer using machine learning models. Front Oncol. 2023;13:1138992. https:\/\/doi.org\/10.3389\/fonc.2023.1138992.","journal-title":"Front Oncol"},{"key":"1798_CR48","doi-asserted-by":"publisher","first-page":"1608505","DOI":"10.3389\/fonc.2025.1608505","volume":"15","author":"Y Tao","year":"2025","unstructured":"Tao Y, Zeng X, Mao H. Predictive models for chemotherapy-induced oral mucositis: a systematic review. Front Oncol. 2025;15:1608505. https:\/\/doi.org\/10.3389\/fonc.2025.1608505.","journal-title":"Front Oncol"},{"key":"1798_CR49","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00520-023-08074-x","volume":"31","author":"DL Hertz","year":"2023","unstructured":"Hertz DL, Lustberg MB, Sonis S. Evolution of predictive risk factor analysis for chemotherapy-related toxicity. Support Care Cancer. 2023;31:601. https:\/\/doi.org\/10.1007\/s00520-023-08074-x.","journal-title":"Support Care Cancer"},{"key":"1798_CR50","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/sj.bjc.6600824","volume":"88","author":"MA Stokman","year":"2003","unstructured":"Stokman MA, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer. 2003;88:1012\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6600824.","journal-title":"Br J Cancer"},{"key":"1798_CR51","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0360-3016(03)01627-4","volume":"58","author":"A Trotti","year":"2004","unstructured":"Trotti A, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004;58:674\u201381. https:\/\/doi.org\/10.1016\/S0360-3016(03)01627-4.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1798_CR52","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1080\/1042819031000079159","volume":"44","author":"FJ Giles","year":"2003","unstructured":"Giles FJ, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leuk Lymphoma. 2003;44:1165\u201372. https:\/\/doi.org\/10.1080\/1042819031000079159.","journal-title":"Leuk Lymphoma"},{"key":"1798_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.radonc.2018.04.023","volume":"129","author":"J Hou","year":"2018","unstructured":"Hou J, et al. Distinct shifts in the oral microbiota are associated with the progression and aggravation of mucositis during radiotherapy. Radiother Oncol. 2018;129:44\u201351. https:\/\/doi.org\/10.1016\/j.radonc.2018.04.023.","journal-title":"Radiother Oncol"},{"key":"1798_CR54","doi-asserted-by":"publisher","first-page":"28706","DOI":"10.1038\/s41598-025-14125-6","volume":"15","author":"A Ue","year":"2025","unstructured":"Ue A, et al. An increase in Fusobacterium is associated with the severity of oral mucositis after radiotherapy. Sci Rep. 2025;15:28706. https:\/\/doi.org\/10.1038\/s41598-025-14125-6.","journal-title":"Sci Rep"},{"key":"1798_CR55","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12032-025-02998-6","volume":"42","author":"FA Boksa","year":"2025","unstructured":"Boksa FA, Leinbach LI, Mody DP, Ganesan SM, Mays JW. Oral microbiome alterations after cancer treatment: a scoping review and analysis. Med Oncol. 2025;42:432. https:\/\/doi.org\/10.1007\/s12032-025-02998-6.","journal-title":"Med Oncol"},{"key":"1798_CR56","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1099\/mic.0.000149","volume":"161","author":"S Pedroso","year":"2015","unstructured":"Pedroso S, et al. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiol (Reading). 2015;161:1950\u201360. https:\/\/doi.org\/10.1099\/mic.0.000149.","journal-title":"Microbiol (Reading)"},{"key":"1798_CR57","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ijrobp.2022.03.036","volume":"113","author":"G Al-Qadami","year":"2022","unstructured":"Al-Qadami G, et al. Antibiotic-Induced Gut Microbiota Depletion Accelerates the Recovery of Radiation-Induced Oral Mucositis in Rats. Int J Radiat Oncol Biol Phys. 2022;113:845\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.03.036.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1798_CR58","doi-asserted-by":"publisher","unstructured":"Zhu XX et al. The Potential Effect of Oral Microbiota in the Prediction of Mucositis During Radiotherapy for Nasopharyngeal Carcinoma. EBioMedicine, 2017, 18, 23\u201331. https:\/\/doi.org\/10.1016\/j.ebiom.2017.02.002","DOI":"10.1016\/j.ebiom.2017.02.002"},{"key":"1798_CR59","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00520-025-09882-z","volume":"33","author":"HR Wardill","year":"2025","unstructured":"Wardill HR, et al. Enteral versus parenteral nutrition in auto-HCT: a randomized controlled trial on clinical outcomes and gut microbiome dynamics. Support Care Cancer. 2025;33:865. https:\/\/doi.org\/10.1007\/s00520-025-09882-z.","journal-title":"Support Care Cancer"},{"key":"1798_CR60","doi-asserted-by":"publisher","unstructured":"Sonis ST. The Chicken or the Egg? Changes in Oral Microbiota as Cause or Consequence of Mucositis During Radiation Therapy. EBioMedicine, 2017 18, 7\u20138. https:\/\/doi.org\/10.1016\/j.ebiom.2017.03.017","DOI":"10.1016\/j.ebiom.2017.03.017"},{"key":"1798_CR61","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/cid\/ciac887","volume":"76","author":"CEM de Mooij","year":"2023","unstructured":"de Mooij CEM, et al. Blautia Abundance and Mucosal Barrier Injury: A Complex Play of Cause and Effect. Clin Infect Dis. 2023;76:1152\u20133. https:\/\/doi.org\/10.1093\/cid\/ciac887.","journal-title":"Clin Infect Dis"},{"key":"1798_CR62","doi-asserted-by":"publisher","first-page":"1941711","DOI":"10.1080\/19490976.2021.1941711","volume":"13","author":"CE Gheorghe","year":"2021","unstructured":"Gheorghe CE, et al. Investigating causality with fecal microbiota transplantation in rodents: applications, recommendations and pitfalls. Gut Microbes. 2021;13:1941711. https:\/\/doi.org\/10.1080\/19490976.2021.1941711.","journal-title":"Gut Microbes"},{"key":"1798_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.archoralbio.2019.03.008","volume":"101","author":"N Gupta","year":"2019","unstructured":"Gupta N, et al. Role of oral flora in chemotherapy-induced oral mucositis in vivo. Arch Oral Biol. 2019;101:51\u20136. https:\/\/doi.org\/10.1016\/j.archoralbio.2019.03.008.","journal-title":"Arch Oral Biol"},{"key":"1798_CR64","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","volume":"126","author":"S Elad","year":"2020","unstructured":"Elad S, et al. MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126:4423\u201331. https:\/\/doi.org\/10.1002\/cncr.33100.","journal-title":"Cancer"},{"key":"1798_CR65","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/1097-0142(20010815)92:4<875::AID-CNCR1396>3.0.CO;2-1","volume":"92","author":"JB Epstein","year":"2001","unstructured":"Epstein JB, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer. 2001;92:875\u201385. https:\/\/doi.org\/10.1002\/1097-0142(20010815)92:4%3C;875::AID-CNCR1396%3E;3.0.CO;2-1.","journal-title":"Cancer"},{"key":"1798_CR66","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1056\/NEJMoa040125","volume":"351","author":"R Spielberger","year":"2004","unstructured":"Spielberger R, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590\u20138. https:\/\/doi.org\/10.1056\/NEJMoa040125.","journal-title":"N Engl J Med"},{"key":"1798_CR67","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/annonc\/mdl332","volume":"18","author":"N Blijlevens","year":"2007","unstructured":"Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol. 2007;18:817\u201326. https:\/\/doi.org\/10.1093\/annonc\/mdl332.","journal-title":"Ann Oncol"},{"key":"1798_CR68","doi-asserted-by":"publisher","first-page":"103606","DOI":"10.1016\/j.critrevonc.2022.103606","volume":"172","author":"J Coutsouvelis","year":"2022","unstructured":"Coutsouvelis J, et al. A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy. Crit Rev Oncol Hematol. 2022;172:103606. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103606.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1798_CR69","doi-asserted-by":"publisher","first-page":"927685","DOI":"10.3389\/fonc.2022.927685","volume":"12","author":"J Robijns","year":"2022","unstructured":"Robijns J, et al. Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022. Front Oncol. 2022;12:927685. https:\/\/doi.org\/10.3389\/fonc.2022.927685.","journal-title":"Front Oncol"},{"key":"1798_CR70","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00520-019-05146-9","volume":"28","author":"S Sonis","year":"2020","unstructured":"Sonis S. Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity? Support Care Cancer. 2020;28:423\u20134. https:\/\/doi.org\/10.1007\/s00520-019-05146-9.","journal-title":"Support Care Cancer"},{"key":"1798_CR71","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1007\/s00520-019-04890-2","volume":"27","author":"Y Zadik","year":"2019","unstructured":"Zadik Y, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27:3969\u201383. https:\/\/doi.org\/10.1007\/s00520-019-04890-2.","journal-title":"Support Care Cancer"},{"key":"1798_CR72","doi-asserted-by":"publisher","unstructured":"Anderson C et al. Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN). EClinicalMedicine 2025, 89. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103539","DOI":"10.1016\/j.eclinm.2025.103539"},{"key":"1798_CR73","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ijrobp.2022.12.031","volume":"116","author":"M Bonomi","year":"2023","unstructured":"Bonomi M, et al. Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2023;116:551\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.12.031.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1798_CR74","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s0360-3016(01)02683-9","volume":"52","author":"D Antonadou","year":"2002","unstructured":"Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739\u201347. https:\/\/doi.org\/10.1016\/s0360-3016(01)02683-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1798_CR75","doi-asserted-by":"publisher","first-page":"e22188","DOI":"10.1002\/ddr.22188","volume":"85","author":"L Liang","year":"2024","unstructured":"Liang L, Sonis ST. Comparisons of successful and failed Phase III trials of drugs and biologicals tested for mitigation of oral mucositis in patients being treated with radiotherapy with or without concomitant chemotherapy for cancers of the head and neck. Drug Dev Res. 2024;85:e22188. https:\/\/doi.org\/10.1002\/ddr.22188.","journal-title":"Drug Dev Res"},{"key":"1798_CR76","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s00520-025-09795-x","volume":"33","author":"R Zuniga","year":"2025","unstructured":"Zuniga R, et al. Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device. Support Care Cancer. 2025;33:732. https:\/\/doi.org\/10.1007\/s00520-025-09795-x.","journal-title":"Support Care Cancer"},{"key":"1798_CR77","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1136\/spcare-2022-003636","volume":"13","author":"R Amiri Khosroshahi","year":"2024","unstructured":"Amiri Khosroshahi R, Talebi S, Travica N, Mohammadi H. Cryotherapy for oral mucositis in cancer: review of systematic reviews and meta-analysis. BMJ Support Palliat Care. 2024;13:e570\u20137. https:\/\/doi.org\/10.1136\/spcare-2022-003636.","journal-title":"BMJ Support Palliat Care"},{"key":"1798_CR78","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00520-023-07989-9","volume":"31","author":"S Oku","year":"2023","unstructured":"Oku S, et al. Protective effect of cryotherapy against oral mucositis among allogeneic hematopoietic stem cell transplant recipients using melphalan-based conditioning. Support Care Cancer. 2023;31:521. https:\/\/doi.org\/10.1007\/s00520-023-07989-9.","journal-title":"Support Care Cancer"},{"key":"1798_CR79","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jama.2019.3504","volume":"321","author":"TT Sio","year":"2019","unstructured":"Sio TT, et al. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. JAMA. 2019;321:1481\u201390. https:\/\/doi.org\/10.1001\/jama.2019.3504.","journal-title":"JAMA"},{"key":"1798_CR80","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00520-019-05181-6","volume":"28","author":"DP Saunders","year":"2020","unstructured":"Saunders DP, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020;28:2473\u201384. https:\/\/doi.org\/10.1007\/s00520-019-05181-6.","journal-title":"Support Care Cancer"},{"key":"1798_CR81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","volume":"23","author":"AD Colevas","year":"2025","unstructured":"Colevas AD, et al. NCCN Guidelines(R) Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025;23:2\u201311. https:\/\/doi.org\/10.6004\/jnccn.2025.0007.","journal-title":"J Natl Compr Canc Netw"},{"key":"1798_CR82","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00520-017-3627-6","volume":"25","author":"A Shillingburg","year":"2017","unstructured":"Shillingburg A, et al. Treatment of severe mucositis pain with oral ketamine mouthwash. Support Care Cancer. 2017;25:2215\u20139. https:\/\/doi.org\/10.1007\/s00520-017-3627-6.","journal-title":"Support Care Cancer"},{"key":"1798_CR83","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/cncr.10938","volume":"95","author":"LC Cerchietti","year":"2002","unstructured":"Cerchietti LC, et al. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer. 2002;95:2230\u20136. https:\/\/doi.org\/10.1002\/cncr.10938.","journal-title":"Cancer"},{"key":"1798_CR84","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/nutrit\/nuac105","volume":"81","author":"R Amiri Khosroshahi","year":"2023","unstructured":"Amiri Khosroshahi R, et al. Nutritional interventions for the prevention and treatment of cancer therapy-induced oral mucositis: an umbrella review of systematic reviews and meta-analysis. Nutr Rev. 2023;81:1200\u201312. https:\/\/doi.org\/10.1093\/nutrit\/nuac105.","journal-title":"Nutr Rev"},{"key":"1798_CR85","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijrobp.2019.10.023","volume":"106","author":"J Giralt","year":"2020","unstructured":"Giralt J, et al. Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2020;106:320\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1798_CR86","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s12094-021-02586-w","volume":"23","author":"A Lozano","year":"2021","unstructured":"Lozano A, et al. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clin Transl Oncol. 2021;23:1801\u201310. https:\/\/doi.org\/10.1007\/s12094-021-02586-w.","journal-title":"Clin Transl Oncol"},{"key":"1798_CR87","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12032-019-1334-5","volume":"37","author":"R Sayed","year":"2019","unstructured":"Sayed R, Wakeel E, Saad L, Kelany AS, M., El-Hamamsy M. Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study. Med Oncol. 2019;37:8. https:\/\/doi.org\/10.1007\/s12032-019-1334-5.","journal-title":"Med Oncol"},{"key":"1798_CR88","doi-asserted-by":"publisher","first-page":"945","DOI":"10.13201\/j.issn.1001-1781.2017.12.012","volume":"31","author":"Y Pan","year":"2017","unstructured":"Pan Y, Wu H, Li Y. [Effect of recombinant human interleukin-11 treatment on prognosis of patients with radiochemoradiotherapy in the treatment of nasopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;31:945\u20138. https:\/\/doi.org\/10.13201\/j.issn.1001-1781.2017.12.012.","journal-title":"Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"1798_CR89","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1200\/JCO.23.00837","volume":"42","author":"X Peng","year":"2024","unstructured":"Peng X, et al. Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial. J Clin Oncol. 2024;42:1426\u201335. https:\/\/doi.org\/10.1200\/JCO.23.00837.","journal-title":"J Clin Oncol"},{"key":"1798_CR90","doi-asserted-by":"publisher","unstructured":"Berkovitz S, Collaco N, Dolakova K, Hughes JA. Systematic Review of Turmeric\/Curcumin for Prevention and Treatment of Oral Mucositis Due to Radiotherapy and\/or Chemotherapy for Head and Neck Cancer. J Integr Complement Med. 2026. https:\/\/doi.org\/10.1177\/27683605261426992.","DOI":"10.1177\/27683605261426992"},{"key":"1798_CR91","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"key":"1798_CR92","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","volume":"43","author":"J Sands","year":"2025","unstructured":"Sands J, et al. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. 2025;43:1254\u201365. https:\/\/doi.org\/10.1200\/JCO-24-01349.","journal-title":"J Clin Oncol"},{"key":"1798_CR93","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn MJ, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2025;43:260\u201372. https:\/\/doi.org\/10.1200\/JCO-24-01544.","journal-title":"J Clin Oncol"},{"key":"1798_CR94","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, et al. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2025;43:285\u201396. https:\/\/doi.org\/10.1200\/JCO.24.00920.","journal-title":"J Clin Oncol"},{"key":"1798_CR95","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, et al. Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024;42:2281\u201394. https:\/\/doi.org\/10.1200\/JCO.23.01909.","journal-title":"J Clin Oncol"},{"key":"1798_CR96","doi-asserted-by":"crossref","unstructured":"Sonis ST et al. Rationale for Effective Interventions to Mitigate Oral Mucositis in Patients Being Treated with TROP-2-Directed Antibody-Drug Conjugates with a Topoisomerase Inhibitor Payload. Oral Oncology In press (2026).","DOI":"10.1016\/j.oor.2026.100784"},{"key":"1798_CR97","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736\u201342. https:\/\/doi.org\/10.1038\/bjc.2017.367.","journal-title":"Br J Cancer"},{"key":"1798_CR98","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1093\/annonc\/mdr484","volume":"23","author":"DM Collins","year":"2012","unstructured":"Collins DM, et al. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 2012;23:1788\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdr484.","journal-title":"Ann Oncol"},{"key":"1798_CR99","doi-asserted-by":"publisher","unstructured":"Meric-Bernstam F, et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis. Oncologist. 2025;30. https:\/\/doi.org\/10.1093\/oncolo\/oyaf031.","DOI":"10.1093\/oncolo\/oyaf031"},{"key":"1798_CR100","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","volume":"49","author":"F Martins","year":"2013","unstructured":"Martins F, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol. 2013;49:293\u20138. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.11.008.","journal-title":"Oral Oncol"},{"key":"1798_CR101","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2217\/fon.13.141","volume":"9","author":"CB Boers-Doets","year":"2013","unstructured":"Boers-Doets CB, et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013;9:1883\u201392. https:\/\/doi.org\/10.2217\/fon.13.141.","journal-title":"Future Oncol"},{"key":"1798_CR102","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/odi.12616","volume":"23","author":"S Sonis","year":"2017","unstructured":"Sonis S, Andreotta PW, Lyng G. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa. Oral Dis. 2017;23:347\u201352. https:\/\/doi.org\/10.1111\/odi.12616.","journal-title":"Oral Dis"},{"key":"1798_CR103","doi-asserted-by":"publisher","unstructured":"Sonis ST, Villa A. A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers (Basel). 2023;16. https:\/\/doi.org\/10.3390\/cancers16010068.","DOI":"10.3390\/cancers16010068"},{"key":"1798_CR104","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/0022034515581012","volume":"94","author":"A Al-Samadi","year":"2015","unstructured":"Al-Samadi A, et al. Epithelial Cell Apoptosis in Recurrent Aphthous Ulcers. J Dent Res. 2015;94:928\u201335. https:\/\/doi.org\/10.1177\/0022034515581012.","journal-title":"J Dent Res"},{"key":"1798_CR105","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/annonc\/mdv595","volume":"27","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016;27:519\u201325. https:\/\/doi.org\/10.1093\/annonc\/mdv595.","journal-title":"Ann Oncol"},{"key":"1798_CR106","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18:654\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(17)30109-2.","journal-title":"Lancet Oncol"},{"key":"1798_CR107","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3109\/07357907.2014.1001893","volume":"33","author":"R Shameem","year":"2015","unstructured":"Shameem R, Lacouture M, Wu S. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Invest. 2015;33:70\u20137. https:\/\/doi.org\/10.3109\/07357907.2014.1001893.","journal-title":"Cancer Invest"},{"key":"1798_CR108","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.oraloncology.2015.09.003","volume":"51","author":"A Yuan","year":"2015","unstructured":"Yuan A, et al. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. Oral Oncol. 2015;51:1026\u201333. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.09.003.","journal-title":"Oral Oncol"},{"key":"1798_CR109","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","volume":"43","author":"AF Galimont-Collen","year":"2007","unstructured":"Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43:845\u201351. https:\/\/doi.org\/10.1016\/j.ejca.2006.11.016.","journal-title":"Eur J Cancer"},{"key":"1798_CR110","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","volume":"25","author":"E Vigarios","year":"2017","unstructured":"Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25:1713\u201339. https:\/\/doi.org\/10.1007\/s00520-017-3629-4.","journal-title":"Support Care Cancer"},{"key":"1798_CR111","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","volume":"55","author":"AL Agero","year":"2006","unstructured":"Agero AL, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55:657\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.010.","journal-title":"J Am Acad Dermatol"},{"key":"1798_CR112","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/14656566.2025.2464106","volume":"26","author":"A Villa","year":"2025","unstructured":"Villa A, Lodolo M, Sonis S. Oral mucosal toxicities in oncology. Expert Opin Pharmacother. 2025;26:481\u20139. https:\/\/doi.org\/10.1080\/14656566.2025.2464106.","journal-title":"Expert Opin Pharmacother"},{"key":"1798_CR113","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00520-024-08689-8","volume":"32","author":"A Villa","year":"2024","unstructured":"Villa A, et al. MASCC\/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy. Support Care Cancer. 2024;32:549. https:\/\/doi.org\/10.1007\/s00520-024-08689-8.","journal-title":"Support Care Cancer"},{"key":"1798_CR114","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.oraloncology.2011.03.028","volume":"47","author":"AL Watters","year":"2011","unstructured":"Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011;47:441\u20138. https:\/\/doi.org\/10.1016\/j.oraloncology.2011.03.028.","journal-title":"Oral Oncol"},{"key":"1798_CR115","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","volume":"17","author":"CB Boers-Doets","year":"2012","unstructured":"Boers-Doets CB, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist. 2012;17:135\u201344. https:\/\/doi.org\/10.1634\/theoncologist.2011-0111.","journal-title":"Oncologist"},{"key":"1798_CR116","doi-asserted-by":"publisher","unstructured":"Xu Y, Wen N, Haddad RI, Sonis ST, Villa A. Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles. Oncologist 2024, 29, e382-e391. https:\/\/doi.org\/10.1093\/oncolo\/oyad279","DOI":"10.1093\/oncolo\/oyad279"},{"key":"1798_CR117","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1200\/OP-24-00812","volume":"21","author":"A Villa","year":"2025","unstructured":"Villa A, Schneider BJ, Lacchetti C, Oliver TK, Peterson DE. Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action. JCO Oncol Pract. 2025;21:1073\u20138. https:\/\/doi.org\/10.1200\/OP-24-00812.","journal-title":"JCO Oncol Pract"},{"key":"1798_CR118","doi-asserted-by":"publisher","unstructured":"Rube CE, et al. Radiation Dermatitis: Radiation-Induced Effects on the Structural and Immunological Barrier Function of the Epidermis. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25063320.","DOI":"10.3390\/ijms25063320"},{"key":"1798_CR119","doi-asserted-by":"publisher","unstructured":"Strandberg J, et al. TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury. J Clin Invest. 2025;135. https:\/\/doi.org\/10.1172\/JCI173649.","DOI":"10.1172\/JCI173649"},{"key":"1798_CR120","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s12035-022-03136-3","volume":"60","author":"CB Subramaniam","year":"2023","unstructured":"Subramaniam CB, et al. 5-Fluorouracil Induces an Acute Reduction in Neurogenesis and Persistent Neuroinflammation in a Mouse Model of the Neuropsychological Complications of Chemotherapy. Mol Neurobiol. 2023;60:1408\u201324. https:\/\/doi.org\/10.1007\/s12035-022-03136-3.","journal-title":"Mol Neurobiol"},{"key":"1798_CR121","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1158\/1078-0432.CCR-11-2000","volume":"18","author":"LA Christie","year":"2012","unstructured":"Christie LA, et al. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res. 2012;18:1954\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2000.","journal-title":"Clin Cancer Res"},{"key":"1798_CR122","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.adro.2018.05.007","volume":"3","author":"N Courtier","year":"2018","unstructured":"Courtier N, Gambling T, Barrett-Lee P, Mason MD. Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy. Adv Radiat Oncol. 2018;3:552\u20138. https:\/\/doi.org\/10.1016\/j.adro.2018.05.007.","journal-title":"Adv Radiat Oncol"},{"key":"1798_CR123","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/cncr.23182","volume":"112","author":"G Aprile","year":"2008","unstructured":"Aprile G, Ramoni M, Keefe D, Sonis S. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer. 2008;112:284\u201392. https:\/\/doi.org\/10.1002\/cncr.23182.","journal-title":"Cancer"},{"key":"1798_CR124","doi-asserted-by":"publisher","first-page":"e70069","DOI":"10.1002\/cncr.70069","volume":"131","author":"D Synnott","year":"2025","unstructured":"Synnott D, O\u2019Reilly D, De Freitas D, Naidoo J. Cytokine release syndrome in solid tumors. Cancer. 2025;131:e70069. https:\/\/doi.org\/10.1002\/cncr.70069.","journal-title":"Cancer"},{"key":"1798_CR125","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000515","volume":"27","author":"DA Cobb","year":"2021","unstructured":"Cobb DA, Lee DW. Cytokine Release Syndrome Biology and Management. Cancer J. 2021;27:119\u201325. https:\/\/doi.org\/10.1097\/PPO.0000000000000515.","journal-title":"Cancer J"},{"key":"1798_CR126","doi-asserted-by":"publisher","first-page":"100860","DOI":"10.1016\/j.bbih.2024.100860","volume":"41","author":"AN Huynh","year":"2024","unstructured":"Huynh AN, et al. Changes in S100 calcium-binding protein beta (S100beta) and cognitive function from pre- to post-chemotherapy among women with breast cancer. Brain Behav Immun Health. 2024;41:100860. https:\/\/doi.org\/10.1016\/j.bbih.2024.100860.","journal-title":"Brain Behav Immun Health"},{"key":"1798_CR127","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s11886-024-02131-5","volume":"26","author":"E Hutchins","year":"2024","unstructured":"Hutchins E, Yang EH, Stein-Merlob AF. Inflammation in Chemotherapy-Induced Cardiotoxicity. Curr Cardiol Rep. 2024;26:1329\u201340. https:\/\/doi.org\/10.1007\/s11886-024-02131-5.","journal-title":"Curr Cardiol Rep"},{"key":"1798_CR128","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bbi.2015.10.016","volume":"52","author":"C Xiao","year":"2016","unstructured":"Xiao C, et al. Fatigue is associated with inflammation in patients with head and neck cancer before and after intensity-modulated radiation therapy. Brain Behav Immun. 2016;52:145\u201352. https:\/\/doi.org\/10.1016\/j.bbi.2015.10.016.","journal-title":"Brain Behav Immun"},{"key":"1798_CR129","doi-asserted-by":"publisher","first-page":"113121","DOI":"10.1016\/j.expneurol.2019.113121","volume":"324","author":"NP Staff","year":"2020","unstructured":"Staff NP, et al. Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. 2020;324:113121. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113121.","journal-title":"Exp Neurol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01798-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01798-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01798-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:01:59Z","timestamp":1792792919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01798-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1798"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01798-z","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated due to a retrospective Open Access order","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hannah Wardill declares no conflict of interest. Stephen Sonis is an employee of Biomodels LLC and Primary endpoint solutions, LLC and is involved in assisting industry government and academics in the study and enablement of drugs, biologicals and devices to treat patients for a broader range of indications including cancer regimen related toxicity disease such as oral mucositis. Alessandro Villa is a consultant for Amgen, GSK, Merck, Mureva, Primary endpoint solutions, and Novartis. He received research grants from NIH, PCCA, MeiraGtx, and Merck.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"60"}}